32 results
8-K
EX-99.1
NVRO
Nevro Corp
7 May 24
Nevro Reports First-Quarter 2024 Financial Results
4:11pm
that continue to set the standard for enduring patient outcomes in chronic pain treatment. The company started with a simple mission to help more
8-K
EX-99.1
NVRO
Nevro Corp
21 Feb 24
Nevro Enters Into Cooperation Agreement With Engaged Capital
4:11pm
for enduring patient outcomes in chronic pain treatment. The company started with a simple mission to help more patients suffering from debilitating pain
8-K
EX-99.1
NVRO
Nevro Corp
21 Feb 24
Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
4:09pm
that continue to set the standard for enduring patient outcomes in chronic pain treatment. The company started with a simple mission to help more patients
8-K
EX-99.1
NVRO
Nevro Corp
9 Jan 24
Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results
8:41am
. This was a difficult decision that impacts some of our team members who have been committed to our mission. We appreciate their dedication and contributions … in chronic pain treatment. The company started with a simple mission to help more patients suffering from debilitating pain and developed its proprietary
8-K
EX-99.1
hwla028224s4dry
1 Dec 23
Nevro Announces Acquisition of Vyrsa™ Technologies
6:07am
8-K
EX-99.1
7gkb5lf6k
1 Nov 23
Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance
4:07pm
8-K
EX-99.1
rvj0p96m41n8y57dm6
1 Aug 23
Nevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 Guidance
4:10pm
8-K
EX-99.1
8mg 169jf
26 Apr 23
Nevro Reports First Quarter 2023 Financial Results, Provides Second Quarter Guidance and Reiterates Full-Year 2023 Guidance
4:13pm
8-K
EX-99.1
xwe9pmxc9 ffq9
19 Apr 23
Results of Operations and Financial Condition
5:07pm
8-K
EX-99.1
bxz714pzer
2 Nov 22
Nevro Reports Third Quarter 2022 Financial Results, Narrows Full-Year 2022 Guidance and Raises Revenue Contribution from Painful Diabetic Neuropathy
4:14pm
8-K
EX-99.1
xd2v9d9ad1sy
3 Aug 22
Nevro Reports Second Quarter 2022 Financial Results, Provides Third Quarter 2022 Guidance and Updates Full-Year 2022 Guidance
4:18pm
8-K
EX-99.1
sg9lqz6fs9c j6n8
1 Aug 22
Other Events
7:11am
8-K
EX-99.1
x8g4 826n
4 May 22
Nevro Reports First Quarter 2022 Financial Results, Provides Second Quarter 2022 Guidance and Reiterates Full-Year 2022 Guidance
4:18pm
8-K
EX-99.1
zes umjtau752
23 Feb 22
Nevro Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides First Quarter and Full-Year 2022 Guidance
12:00am
8-K
EX-99.1
ks960i6zy nwhkru9
10 Jan 22
Nevro Announces Preliminary, Unaudited Fourth Quarter and Fourth Quarter 2021 Worldwide Revenue of Approximately $102.5 Million
6:12am
8-K
EX-99.1
askhr2wpj63i
5 May 20
Nevro Reports First Quarter 2020 Financial Results
4:16pm